Purpose The activity and toxicity of paclitaxel plus carboplatin combination in patients with
disease progression after initial chemotherapy for small-cell lung cancer (SCLC) was …

PURPOSE: To evaluate the efficacy and safety of paclitaxel and carboplatin in the treatment
of previously untreated patients with metastatic small-cell lung cancer (SCLC). PATIENTS …

PURPOSE: The aim of the present phase II study was to evaluate the efficacy of the
paclitaxel, ifosfamide, and cisplatin (PIC) combination in relapsed small-cell lung cancer …

It has demonstrated promising single-agent activity against non–small-cell lung cancer. The
purpose of this study was to evaluate the therapeutic effectiveness of paclitaxel in previously …

PURPOSE To evaluate the efficacy and safety of paclitaxel (Taxol; Bristol-Myers Squibb Co,
Princeton, NJ), a novel diterpene plant product in the treatment of previously untreated …

Purpose Paclitaxel (P) and gemcitabine (G) are clinically synergistic in small cell lung
cancer (SCLC). We evaluated the efficacy of PG as a salvage treatment for SCLC patients …

7211 Background: pts non-responding to 1st line chemotherapy or relapsing within 3
months (m) of confirmed prior response are considered refractory to treatment and candidate …

Purpose To determine the 1-year survival, response rate (RR), time to progression (TTP),
and safety of weekly paclitaxel plus carboplatin (PC) in patients with extensive small-cell …

Purpose: The safety and efficacy of weekly chemotherapy with paclitaxel and carboplatin for
the treatment of patients with refractory or relapsed small-cell lung cancer (SCLC) were …

Cisplatin-paclitaxel and cisplatin-etoposide combination therapies were compared in limited
and extensive disease in patients with small-cell lung cancer. The primary objectives were to …